Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 1 art units • 2 examiners • 0 of 3 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Spruce Biosciences Inc. currently has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are handled by 2 distinct examiners and are all located within 1 distinct art unit. This concentration in a single art unit suggests a focused technical review of the company's pharmaceutical innovations.
The busiest examiner, LEE, WILLIAM Y, is responsible for 2 pending office actions. The remaining pending action is assigned to the other distinct examiner. This distribution shows that a single examiner is managing the majority of the company's current workload within the Biotechnology & Pharmaceuticals area. Having 3 pending office actions reviewed by only 2 distinct examiners within 1 distinct art unit indicates consistency in the prosecution process. LEE, WILLIAM Y handles 2 pending office actions as part of this specialized review.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 3 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, WILLIAM Y | 2 | 47.9% | +34.1% |
| RAHMANI, NILOOFAR | 1 | 77.5% | -2.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18438060 | METHODS OF TREATING CONGENITAL ADRENAL HYPERPLASIA | LEE, WILLIAM Y | — |
| 17578149 | METHODS OF TREATING CONGENITAL ADRENAL HYPERPLASIA | LEE, WILLIAM Y | — |
| Art Unit | Apps |
|---|---|
| 1623 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18785556 | METHODS AND COMPOSITIONS FOR TREATING POLYCYSTIC OVARY SYNDROME | RAHMANI, NILOOFAR | — | §112DP | Non-Final OA | — | Pending | Jul 26, 2024 |
| 18438060 | METHODS OF TREATING CONGENITAL ADRENAL HYPERPLASIA | LEE, WILLIAM Y | 1623 | §103§112DP | Final Rejection | — | Pending | Feb 09, 2024 |
| 17578149 | METHODS OF TREATING CONGENITAL ADRENAL HYPERPLASIA | LEE, WILLIAM Y | 1623 | §103DP | Final Rejection | — | Pending | Jan 18, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial